The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 1st 2024
Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.
Dr. Lallas on Understanding Immunotherapy in GU Malignancies
September 6th 2017Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.
Pembrolizumab Approved in Europe for Urothelial Carcinoma
September 6th 2017The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.
Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer
August 28th 2017Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.
Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer
August 25th 2017Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.
Frontline Nivolumab/Ipilimumab Improves Response in mRCC
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved the objective response rate and duration of response compared with sunitinib (Sutent) in patients with treatment-naïve metastatic renal cell carcinoma, according to CheckMate-214.
Dr. Atkins Discusses Response to Atezolizumab in RCC
August 16th 2017Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma.
Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer
August 15th 2017Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.
Dr. Chowdhury on Sequencing of Immunotherapy Regimens for RCC
August 8th 2017Simon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).
Dr. Atkins on Sequencing of Immunotherapy Combination Regimens
August 3rd 2017Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).
Dr. Balar on PD-L1 Testing for Urothelial Cancer
August 2nd 2017Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, Perlmutter Cancer Center, NYU Langone Medical Center, discusses PD-L1 testing and the development of biomarkers for PD-L1 antibodies for patients with urothelial carcinoma.
Dr. Atkins on Excitement With Atezolizumab and Bevacizumab in RCC
July 27th 2017Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the excitement surrounding the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).